Analysts’ Weekly Ratings Updates for Twist Bioscience (TWST)

A number of firms have modified their ratings and price targets on shares of Twist Bioscience (NASDAQ: TWST) recently:

• 8/5/2026 – Twist Bioscience had its price target raised by Piper Sandler from $85.00 to $115.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Twist Bioscience had its price target raised by Robert W. Baird from $113.00 to $115.00. They now have an “outperform” rating on the stock.
• 8/3/2026 – Twist Bioscience had its “buy” rating reaffirmed by TD Cowen.
• 7/16/2026 – Twist Bioscience was given a new $110.00 price target by Leerink Partners.
• 7/14/2026 – Twist Bioscience had its price target raised by Canaccord Genuity Group Inc. from $90.00 to $120.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Twist Bioscience was downgraded by Evercore Inc from “outperform” to “in-line”. They now have a $102.00 price target on the stock.
• 6/29/2026 – Twist Bioscience had its price target raised by Guggenheim from $60.00 to $107.00. They now have a “buy” rating on the stock.
• 6/24/2026 – Twist Bioscience had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/24/2026 – Twist Bioscience had its price target raised by Barclays PLC from $65.00 to $95.00. They now have an “overweight” rating on the stock.
• 6/15/2026 – Twist Bioscience had its price target raised by TD Cowen from $68.00 to $89.00. They now have a “buy” rating on the stock.
• 6/15/2026 – Twist Bioscience is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $90.00 price target on the stock.
• 6/15/2026 – Twist Bioscience was given a new $89.00 price target by UBS Group AG.
• 6/15/2026 – Twist Bioscience had its price target raised by TD Cowen from $68.00 to $89.00. They now have a “buy” rating on the stock.
• 6/15/2026 – Twist Bioscience is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $90.00 price target on the stock.
• 6/11/2026 – Twist Bioscience is now covered by Piper Sandler. They set an “overweight” rating and a $85.00 price target on the stock.
• 6/11/2026 – Twist Bioscience is now covered by Piper Sandler. They set an “overweight” rating and a $85.00 price target on the stock.

Insider Buying and Selling

In other Twist Bioscience news, CFO Adam Laponis sold 2,399 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $94.33, for a total transaction of $226,297.67. Following the sale, the chief financial officer directly owned 110,276 shares of the company’s stock, valued at approximately $10,402,335.08. This trade represents a 2.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jan Johannessen sold 12,000 shares of Twist Bioscience stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $56.12, for a total value of $673,440.00. Following the transaction, the director owned 17,754 shares of the company’s stock, valued at $996,354.48. The trade was a 40.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 50,211 shares of company stock valued at $4,199,331 in the last 90 days. 3.08% of the stock is currently owned by insiders.

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.